Second, different PD-L1 expression levels did not affect the efficacy of first-line EGFR-TKIs in treating stage IV EGFR mutant lung adenocarcinoma patients, neither in response nor TTF. This evidence concerns the gene EGFR and lung adenocarcinoma.